Categories: Health

Monthly information on share capital and company voting rights

PARIS, July 04, 2025 (GLOBE NEWSWIRE) —

(Article 223-16 of General Regulation of the French financial markets authority)

Listing market: Euronext Growth

ISIN code: FR0010425595

Date Total number of shares
in the capital
Total number of voting rights
06/30/2025 100,325,229 89,428,630

For further information on Cellectis, please contact:     

Media contacts:       

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:       

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

GlobeNews Wire

Recent Posts

Movate and Reef.ai Partner to Empower Enterprises with AI-Powered Churn Prediction and Retention Solutions

BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- Movate, a global leader in digital technology and customer…

3 hours ago

NABR Comment on IUCN Determination

WASHINGTON, Oct. 13, 2025 /PRNewswire/ -- The International Union for Conservation of Nature (IUCN) issued…

3 hours ago

Green Street Brings Its Industry-Leading Public Market Research and REIT Data to Australia – Expanding Global CRE Intelligence

SYDNEY, Oct. 14, 2025 /PRNewswire/ -- Green Street, the leading provider of trusted commercial real estate…

4 hours ago

FROM FRYING OIL TO COUPLING RELAYS: SIEMENS AND ENVALIOR COLLABORATE ON MORE SUSTAINABLE ELECTRICAL PRODUCTS

Siemens launches new SIRIUS 3RQ4 coupling relay with three versatile variants for a wide range…

4 hours ago

Apollomics, Inc. Company Operational Continuity Update

October 13, 2025 21:22 ET  | Source: Apollomics Inc. FOSTER CITY, Calif., Oct. 13, 2025…

5 hours ago

Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”)…

5 hours ago